Chordate Medical begins market introduction of migraine treatment in the UK

Chordate Medical (publ) (“Chordate”, “the company”) has entered into an agreement with Futures.Health LTD, UK to introduce the company’s product for preventive migraine treatment on the UK market. The agreement is initially signed for one year and has been preceded by a detailed market analysis to determine the best approach – carried out by Futures.Health.

The agreement means that Futures.Health on behalf of Chordate will introduce the K.O.S treatment to opinion-leading neurologists in the UK, primarily in the private health sector, and spread knowledge about K.O.S and the company. The agreement also includes that Futures.Health will organize marketing activities and bring about sales at an early stage. At the same time, Chordate terminates the agreement with the company’s former distributor in the UK.

According to the NHS, around 10 million people aged 15-69 suffer from migraines in the UK. In total, the NHS estimates that it spends around £ 150 million a year on treating migraines and £ 250 million on the care of headache patients. The cost to the national economy is around £ 4.4 billion a year lost to three million migraine-related sick days.

“After an in-depth analysis of the market that has been ongoing since last summer, it’s positive that we have now started the project. We have a lot of work ahead of us, but based on the market access analysis, I have full confidence in the expertise of Futures.Health. To introduce a specialist care product to a new market requires focused individual competence in the healthcare market’s structure, academia, compensation issues and marketing, and Futures.Health have just that”, says Anders Weilandt, CEO of Chordate.

This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on February 11th, 2022, at 08:40 a.m. CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

Vastra Hamnen Corporate Finance AB, +46 40 200 250,, is Chordate’s Certified Adviser.

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy